Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study

What Was Tested

The paper reports a study of Calcitonin in the context of osteoporosis and bone density, published as a randomized controlled trial.

The aim of this study was to compare the clinical and metabolic effect of intranasal (in) and intramuscular (im) hCT in patients with osteoporosis or with Paget's disease of bones.

Why It Was Studied

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

Six women in each group were treated for 2 months, and only four women in each group continued treatment for an additional 4 months period.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Calcitonin and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Calcitonin study would be practical.

The timeline in the abstract includes 2 months.

What Was Measured

The subject headings attached to it are Bone Density, Calcitonin, Cyclic AMP, Osteitis Deformans, Osteoporosis, Osteoporosis, Postmenopausal and Pain.

What This Means in Plain Language

The paper is a randomized and pilot study of Calcitonin in people with osteoporosis and bone density over 2 months.

The publication is from 1991 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Calcitonin compound page, Osteoporosis and bone density research.